Low-Dose Irradiation Differentially Impacts Macrophage Phenotype in Dependence of Fibroblast-Like Synoviocytes and Radiation Dose.
Animals
Arthritis, Rheumatoid
/ immunology
B7-1 Antigen
/ metabolism
B7-2 Antigen
/ metabolism
Cell Differentiation
Cells, Cultured
Cytokines
/ metabolism
Disease Models, Animal
Humans
Inflammation
/ immunology
Lectins, C-Type
/ metabolism
Macrophage Activation
/ radiation effects
Macrophages
/ immunology
Mannose Receptor
Mannose-Binding Lectins
/ metabolism
Mice
Mice, Transgenic
Phenotype
Radiation Dosage
Receptors, Cell Surface
/ metabolism
Synoviocytes
/ metabolism
Tumor Necrosis Factor-alpha
/ genetics
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
02
2019
revised:
01
07
2019
accepted:
11
07
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
25
1
2020
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease whose main hallmark is inflammation and destruction of the joints. Two cell types within the synovium that play an important role in RA are fibroblast-like synoviocytes (FLS) and macrophages. The latter innate immune cells show a high plasticity in their phenotype and are central in inflammatory processes. Low-dose radiotherapy (LD-RT) with particularly a single dose of 0.5 Gy has been demonstrated to have a positive impact on pain, inflammation, and bone in inflamed joints. We now examined for the first time how LD-RT influences FLS and bone marrow-derived macrophages in co-culture systems of an experimental model of RA to reveal further mechanisms of immune modulatory effects of low and intermediate dose of ionizing radiation. For this, the bone marrow of h
Identifiants
pubmed: 31485459
doi: 10.1155/2019/3161750
pmc: PMC6710796
doi:
Substances chimiques
B7-1 Antigen
0
B7-2 Antigen
0
Cytokines
0
Lectins, C-Type
0
Mannose Receptor
0
Mannose-Binding Lectins
0
Receptors, Cell Surface
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3161750Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Int J Radiat Biol. 1999 Aug;75(8):995-1003
pubmed: 10465365
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):195-202
pubmed: 10758324
Arthritis Res. 2000;2(3):189-202
pubmed: 11094428
N Engl J Med. 2001 Mar 22;344(12):907-16
pubmed: 11259725
Ann Rheum Dis. 2005 Jun;64(6):834-8
pubmed: 15576415
Int J Radiat Biol. 2007 Jun;83(6):357-66
pubmed: 17487675
Arthritis Res Ther. 2007;9(6):223
pubmed: 18177509
Arthritis Res Ther. 2007;9(6):224
pubmed: 18177511
Curr Med Res Opin. 2008 Aug;24(8):2283-94
pubmed: 18590608
Blood. 2009 Nov 19;114(21):4613-23
pubmed: 19696199
Nat Rev Rheumatol. 2009 Oct;5(10):554-9
pubmed: 19798030
Trends Mol Med. 2010 Oct;16(10):458-68
pubmed: 20739221
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21105-10
pubmed: 22160723
J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):68-75
pubmed: 22265957
Curr Med Chem. 2012;19(12):1741-50
pubmed: 22414082
Int J Radiat Biol. 2012 Oct;88(10):727-34
pubmed: 22545750
Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v3-11
pubmed: 22718924
Strahlenther Onkol. 2012 Nov;188(11):975-81
pubmed: 22907572
Arthritis Rheum. 2012 Dec;64(12):3856-66
pubmed: 22941906
Front Oncol. 2012 Sep 25;2:120
pubmed: 23057008
Autoimmunity. 2013 Aug;46(5):323-8
pubmed: 23215648
Biotechnol J. 2013 Apr;8(4):395-6
pubmed: 23554248
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10729-34
pubmed: 23754379
J Vis Exp. 2013 Jun 23;(76):null
pubmed: 23851980
Strahlenther Onkol. 2014 Mar;190(3):293-7
pubmed: 24424629
Radiat Oncol. 2014 Mar 22;9:80
pubmed: 24655916
Clin Exp Immunol. 2015 Jan;179(1):50-61
pubmed: 24730395
J R Soc Interface. 2014 Jul 6;11(96):null
pubmed: 24829281
Strahlenther Onkol. 2015 Jan;191(1):1-6
pubmed: 25238992
Ann Rheum Dis. 2016 Feb;75(2):413-21
pubmed: 25414238
Cancer Lett. 2015 Nov 28;368(2):173-8
pubmed: 25681669
Strahlenther Onkol. 2015 Sep;191(9):742-9
pubmed: 26051282
Sci Rep. 2016 Jan 06;6:18765
pubmed: 26735768
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Int Immunopharmacol. 2017 Sep;50:345-352
pubmed: 28750350
J Biomed Mater Res A. 2017 Nov;105(11):3069-3076
pubmed: 28782174
Sci Rep. 2017 Aug 21;7(1):8965
pubmed: 28827726
Immunol Rev. 2017 Nov;280(1):231-248
pubmed: 29027224
PLoS One. 2018 Jan 19;13(1):e0191402
pubmed: 29351567
Front Immunol. 2018 Jan 08;8:1958
pubmed: 29375576
Front Immunol. 2018 Jan 23;8:1933
pubmed: 29410662
Immunology. 2018 Jun;154(2):186-195
pubmed: 29455468
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
Int J Radiat Biol. 2018 Aug;94(8):727-736
pubmed: 29569509
Toxicol Res (Camb). 2015 Aug 11;5(1):12-33
pubmed: 30090323
Front Immunol. 2018 Sep 18;9:1834
pubmed: 30279685
Int J Mol Sci. 2018 Oct 16;19(10):null
pubmed: 30332826
Int J Mol Sci. 2018 Nov 13;19(11):null
pubmed: 30428512
Strahlenther Onkol. 2019 Apr;195(4):285-288
pubmed: 30564845
Ann Rheum Dis. 2018 Dec 21;:null
pubmed: 30578294
Cell. 1996 May 3;85(3):307-10
pubmed: 8616886